CEPH, Cephalon Inc.

 CEPH, Cephalon Inc.

CEPH is a biopharmaceutical company that engages in the discovery, development and commercializations of products for the central nervous system, inflammatory disease, pain and oncology therapeutic areas.

 

CEPH reported that it has received an unsolicited proposal from Valeant Pharmaceuticals International Inc., on March 18 to acquire the company for $73 per share and a second unsolicited proposal on March 25th to either acquire CEPH for $73 per share or to purchase CEPH’s non-oncology related assets for $2.8 billion. On March 29th, Valeant announced an unsolicited proposal to acquire all of the outstanding shares in CEPH for $73 per share.

Upon receiving each of Valeant’s proposals, CEPH acted expeditiously to commence an analysis of both alternatives presented by Valeant. CEPH advised Valeant that it is working with its financial advisors to review and consider each proposal. In addition, CEPH advised Valeant that its Board of Directors would be meeting to consider the proposals and planned to respond to Valeant during the week of April 4th.

CEPH has the distinction of being one of the world’s fastest-growing biopharmaceutical companies, now among the Fortune 1000 and a member of the S&P 500 Index. CEPH sells numerous branded and generic products around the world. In total, Cephalon sells more than 150 products in nearly 100 countries.

CEPH achieved record-setting performance in 2010. CEPH has seen a 28 percent increase in net sales over 2009 to $2.76 billion, and a 40 percent increase in adjusted net income over 2009 to $657 million.
http://www.cephalon.com/